GlassScriptPhysician profile
Tracie D Smith
NPI 1053381319
$2,170.88
in general payments reported to CMS, 2019-2025
24 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $547 · 2023: $330 · 2024: $432 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $273.23 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $264.97 | 2021-2025 | Breztri, Andexxa |
| Sanofi-Aventis U.S. LLC | $168.68 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $162.07 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $153.21 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $143.38 | 2021-2022 | |
| Amgen INC. | $138.20 | 2023-2024 | Tezspire, Repatha |
| Regeneron Healthcare Solutions, INC. | $136.70 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.64 | 2022-2024 | Ofev, Jardiance |
| Atricure, INC. | $124.86 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $66.03 | 2024-2025 | Opsumit |
| Pfizer INC. | $55.12 | 2022 | |
| Merck Sharp & Dohme LLC | $49.69 | 2021-2023 | Verquvo |
| Biosense Webster, INC. | $42.31 | 2021 | |
| Boston Scientific Corporation | $40.09 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $38.41 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $35.56 | 2023 | Hillrom - Life 2000 Ventilation System |
| Novo Nordisk INC | $26.47 | 2021 | |
| Lundbeck LLC | $23.80 | 2025 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $20.50 | 2024 | |
| Genzyme Corporation | $19.70 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.47 | 2025 | Glassia |
| United Therapeutics Corporation | $19.39 | 2024 | Tyvaso |
| Kiniksa Pharmaceuticals, LTD. | $17.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.